Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...
Fallout: New Vegas lead writer John Gonzalez returns to developer Obsidian after 14 years, but he doesn't want you to get your hopes up – it isn't for a New Vegas sequel. It's simply "for exciting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback